NCT01150500已完成不适用
RESOLUTE JAPAN SVS: The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries
Medtronic Vascular2 个研究点 分布在 1 个国家目标入组 65 人开始时间: 2010年6月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 65
- 试验地点
- 2
- 主要终点
- Target Lesion Failure(TLF)
研究概览
简要总结
The objective of the study is To verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) that allows the use of 2.25mm diameter stents.
详细描述
The objective of the study is to verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) that allows the use of 2.25mm diameter stents.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acceptable candidate for percutaneous coronary intervention (PCI),stenting, and emergency coronary artery bypass graft surgery
- •Clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia and/or positive functional study
- •Informed consent
- •Patient agrees to comply with specified follow-up evaluations at same investigational site
- •Single target lesion or two target lesions located in separate coronary arteries
- •De novo lesion(s) in native coronary artery(ies)
- •Target lesion(s) ≤ 27 mm in length
- •Target vessel(s) have reference vessel diameter 2.25 mm to 3.5 mm
排除标准
- •Within 7 days of implant platelet count <100,000 cells/mm³ or >700,000 cells/mm³; White Blood Cell (wbc) count <3,000 cells/mm³; serum creatinine level >2.5 mg/dl
- •Acute myocardial infarction (MI) within 72 hrs of the index procedure (Q wave myocardial infarction(QWMI)/non Q wave myocardial infarction (NQMI) or any elevation of creatinine kinease myocardial-band isoenzyme(CK-MB) > lab upper limit of normal)
- •Previous PCI of target vessel(s) within 9 months prior to the procedure
- •Planned PCI of any vessel within 30 days post-index procedure and/or planned PCI of target vessel(s) within 12 months post-index procedure
- •History of stroke or transient ischemic attack(TIA) within prior 6 months
- •Participating in investigational drug/device study that has not completed primary endpoint or interferes with study endpoints
- •Inability to comply with required trial antiplatelet regimen
- •Previous stent in target vessel unless it has been at least 9 months since stent placed and target lesion(s) is/are at least 15 mm from previous stent
- •Target vessel(s) has/have other lesions w/ > 40% diameter stenosis
- •Unprotected left main coronary artery disease
结局指标
主要结局
Target Lesion Failure(TLF)
时间窗: 9 month
Target Lesion Failure (TLF) at 9 months post-procedure defined as a composite measure of cardiac death, heart attack attributed to the target vessel (target vessel myocardial infarction), and ischemia-driven target lesion revascularization (TLR)
次要结局
- Clinical Endpoints(5 Years)
- Binary Angiographic Restenosis(Baseline and 9 month)
- Percent Diameter Stenosis(Baseline and 9 month)
- Late Lumen Loss(Baseline and 9 months)
- MACE (Major Adverse Cardiac Event)(Baseline and 9 month)
- Minimum Luminal Diameter(9 month)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
RESOLUTE Japan - The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary StentArterial Occlusive DiseasesCardiovascular DiseasesCoronary Artery DiseaseMyocardial IschemiaNCT00927940Medtronic Vascular100
已完成
不适用
Clinical Evaluation of MDT-2111 in Subjects With Small Aortic Annuli and Symptomatic Severe Aortic StenosisAortic Valve StenosisNCT01634269Medtronic Cardiovascular20
已完成
不适用
Clinical Evaluation of MDT-2111 in Subjects With Symptomatic Severe Aortic StenosisAortic Valve StenosisNCT01437098Medtronic Cardiovascular55
已完成
不适用
Safety and Effectiveness of an Auricular SprayExcessive Ear WaxNCT06085443YSLab99
已完成
1 期
A Study of LY3209590 in Japanese Participants With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT04276428Eli Lilly and Company28